Adjuvant chemotherapy in small node-negative triple-negative breast cancer
- 1 August 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 135, 66-74
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Merck
- Novartis
- Roche
- AstraZeneca
- BMS
- Roche
- Agendia
- Amgen
- AstraZeneca
- BMS
- Genentech
- Roche
- Sanofi
- Tesaro
This publication has 43 references indexed in Scilit:
- Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancerThe Breast, 2019
- Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective studyEuropean Journal of Cancer, 2017
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017Journal of the National Comprehensive Cancer Network, 2017
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast CancerClinical Breast Cancer, 2014
- Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional StudyJournal of Clinical Oncology, 2014
- Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodesAnnals of Oncology, 2013
- Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer SubtypeClinical Breast Cancer, 2011
- Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast CarcinomaJournal of Clinical Oncology, 2007
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007